{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:10:41Z","timestamp":1761894641837},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1053\/j.seminoncol.2007.11.006","type":"journal-article","created":{"date-parts":[[2008,1,7]],"date-time":"2008-01-07T12:19:03Z","timestamp":1199708343000},"page":"S21-S28","source":"Crossref","is-referenced-by-count":32,"special_numbering":"S5","title":["Mycosis Fungoides: Pathophysiology and Emerging Therapies"],"prefix":"10.1053","volume":"34","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2007.11.006_bib1","first-page":"561","article-title":"Proceeding of the workshop on cutaneous T-cell lymphomas (mycosis fungoides and S\u00e9zary syndromes)","volume":"63","author":"Lamberg","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib3","first-page":"413","article-title":"Description des maladies de la peau observees a l\u2019h\u00f4pital St Louis","volume":"1","author":"Alibert","year":"1806","journal-title":"Barrois L\u2019aine et Fils"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib4","unstructured":"Bazin PAE: Maladies de la peau observees a l\u2019h\u00f4pital St Louis, 1876."},{"key":"10.1053\/j.seminoncol.2007.11.006_bib5","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib6","first-page":"453","article-title":"On the erythrodermia of mycosis fungoides","volume":"10","author":"Besnier","year":"1892","journal-title":"J Cutan Genito Urin Dis"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib7","first-page":"725","article-title":"Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood.V69.3.841.841","article-title":"Evaluation of circulating malignant cells provides prognostic information in cutaneous T-cell lymphoma","volume":"69","author":"Schechter","year":"1987","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: Clinical prognostic factors and risk for disease progression","volume":"39","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2133.1974.tb12449.x","article-title":"Mycosis fungoides: A disease of antigen persistence","volume":"91","author":"Tan","year":"1974","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.immunol.19.1.375","article-title":"The immunological synapse","volume":"19","author":"Bromley","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib12","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archderm.129.4.433","article-title":"Peripheral blood mononuclear cells in non-leukemic cutaneous-cell lymphoma patients: Reduced proliferation and preferential secretion of a T helper 2 like cytokine pattern on stimulation","volume":"129","author":"Drummer","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1396-0296.2003.01637.x","article-title":"Diagnosis, staging, and monitoring of cutaneous T-cell lymphoma","volume":"16","author":"Wood","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib15","first-page":"2682","article-title":"Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in Mycosis fungoides: A potential mechanism of tumor immune escape?","volume":"7","author":"Xiao","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1540-9740.2003.02258.x","article-title":"Topical imiquimod therapy for cutaneous T-cell lymphoma","volume":"2","author":"Do","year":"2003","journal-title":"Skinmed"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14656566.7.7.907","article-title":"Bexarotene in the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Querfeld","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib21","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib22","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): Two phase II studies in refractory cutaneous T-cell lymphoma","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2007.11.006_bib23","first-page":"937a","article-title":"Phase I trial of siplizumab in CD2-positive lymphoproliferative disease","volume":"106","author":"O\u2019Mahony","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib24","doi-asserted-by":"crossref","first-page":"768a","DOI":"10.1182\/blood.V108.11.2718.2718","article-title":"SGN-30 (Anti-CD30 mAb) has a single-agent response rate of 21% in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)","volume":"108","author":"Forero-Torres","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.2001.tb03721.x","article-title":"The role for interleukin-12 therapy of cutaneous T-cell lymphoma","volume":"941","author":"Rook","year":"2001","journal-title":"Ann NY Acad Sci"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib26","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3816\/CLM.2001.n.005","article-title":"Biological correlates of acute hypersensitivity with DAB(389) IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication","volume":"1","author":"Foss","year":"2001","journal-title":"Clin Lymphoma"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2001.tb03705.x","article-title":"Cutaneous T cell lymphoma: The helping hand of dendritic cells","volume":"941","author":"Edelson","year":"2001","journal-title":"Ann NY Acad Sci"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib30","first-page":"1","article-title":"Emerging drugs in cutaneous T-cell lymphoma","volume":"10","author":"Drummer","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib31","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: Causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib33","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib34","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","article-title":"Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action","volume":"125","author":"Zhang","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib35","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"A phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib36","doi-asserted-by":"crossref","first-page":"71a","DOI":"10.1182\/blood.V106.11.231.231","article-title":"Completion of the first cohort of patients with cutaneous T-cell lymphoma enrolled on a phase II trial of depsipeptide","volume":"106","author":"Piekarz","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib37","first-page":"422s","article-title":"LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTLC): Changes in skin gene expression profiles related to clinical response following therapy","volume":"24","author":"Prince","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib38","first-page":"483","volume":"vol 7","author":"Parks","year":"1972"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib39","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(75)91950-9","article-title":"Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity","volume":"1","author":"Giblett","year":"1975","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib40","first-page":"45","article-title":"Purine nucleoside phosphorylase deficiency","volume":"3","author":"Markert","year":"1991","journal-title":"Immunodefic Rev"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib41","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1567-5769(03)00076-6","article-title":"Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777","volume":"3","author":"Bantia","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib42","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.0022-202X.2005.23657.x","article-title":"Resistance to activation-induced cell death and bystander cytotoxicity via the Fas\/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas","volume":"124","author":"Ni","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0037-1963(00)90055-6","article-title":"Apoptosis and cancer: strategies for integrating cell death","volume":"37","author":"Reed","year":"2000","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib44","first-page":"243","article-title":"Purine nucleoside phosphorylase inhibitors in T-cell malignancies","volume":"7","author":"Bantia","year":"2004","journal-title":"Curr Opin Drug Dis Dev"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib45","doi-asserted-by":"crossref","first-page":"8615","DOI":"10.1021\/bi980658d","article-title":"One-third-the-sites transition-state inhibitors to purine nucleoside phosphorylase","volume":"37","author":"Miles","year":"1998","journal-title":"Biochemistry"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib46","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1567-5769(01)00056-X","article-title":"Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)\u2014A novel potent and orally active immunosuppressive agent","volume":"1","author":"Bantia","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib47","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1073\/pnas.071050798","article-title":"Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase selectively inhibits human T lymphocytes","volume":"98","author":"Kicska","year":"2001","journal-title":"Proc Nat Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib48","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1567-5769(03)00076-6","article-title":"Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777","volume":"3","author":"Bantia","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib49","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1567-5769(02)00034-6","article-title":"Comparison of in vivo efficacy of BCX-1777 and cyclosporine in xenogeneic graft-vs.-host disease: The role of dGTP in antiproliferative action of BCX-1777","volume":"2","author":"Bantia","year":"2002","journal-title":"Int Immunopharmacol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib50","first-page":"683a","article-title":"Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma","volume":"104","author":"Duvic","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mjd.2003.449","article-title":"Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma","volume":"49","author":"Duvic","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib52","doi-asserted-by":"crossref","first-page":"750a","DOI":"10.1182\/blood.V104.11.2743.2743","article-title":"Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I\/II studies in patients with B-cell acute lymphoblastic leukemia","volume":"104","author":"Furman","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib53","doi-asserted-by":"crossref","first-page":"259a","DOI":"10.1182\/blood.V106.11.881.881","article-title":"Forodesine (Fodosine), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (phase III study)","volume":"106","author":"Furman","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib54","first-page":"208b","article-title":"Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, in phase I\/II trials in patients with advanced T-cell malignancies","volume":"104","author":"Isola","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib55","first-page":"613a","article-title":"Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma","volume":"22","author":"Duvic","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2007.11.006_bib56","first-page":"698a","article-title":"Oral forodesine (BCX-1777) is clinically active in refractory cutaneous T-cell lymphoma: Results of a phase I\/II study","volume":"108","author":"Duvic","year":"2006","journal-title":"Proc Am Soc Hematol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775407002254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T11:39:48Z","timestamp":1588246788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775407002254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":55,"alternative-id":["S0093775407002254"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2007.11.006","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}